AD04 for early Alzheimer's disease
phase 2drug program · high · Fri Sep 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate AD04 as a potential disease-modifying therapy for patients with early Alzheimer's disease.
Randomized, placebo-controlled phase 2b ADVANCE study assessing safety, pharmacodynamics, and efficacy; AD04 is described as an immuno-stimulant/aluminum oxyhydroxide vaccine adjuvant.
Awarded a $2.5 million NIH SBIR grant on 2025-09-26 to advance AD04 toward the clinic; ADVANCE phase 2b trial is listed in public records.
Post hoc AFF006 analyses reported treatment benefit for AD04 after multiplicity adjustment and estimated 11 months saved in an 18-month study for the AD04 2 mg group; authors state findings are hypothesis-generating and motivated the ADVANCE randomized trial.